Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer United States Business Strategies

MusclePharm Chairman Flexes Financial Support, Board Influence

This article was originally published in The Tan Sheet

  • News

Executive Summary

Ryan Drexler buys a $6m promissory note bearing 8% annual interest, convertible to shares priced at $2.30, two months after committing $6.2m to guarantee existing bank loans for the sports nutrition firm.

You may also be interested in...



MusclePharm Sheds 75% Of Portfolio, Flexes After Spending Stretched It Thin

MusclePharm whittled its product line from 450 to 120 SKUs  and is shifting its distribution focus in the US from specialty retail to Amazon and Costco. The firm also cut operating costs, spending $10m less in 2017 than in 2016.

AHPA Comments On Vinpocetine: Health And Wellness Industry News Roundup

AHPA argues FDA erred in vinpocetine proposal; and MusclePharm CEO bails out firm again.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Table

View full table

Topics

Tags:
Consumer United States Business Strategies
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS108069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By